Biotech

All Articles

TPG leadings up funds to $580M for assets across lifestyle scientific researches

.Asset supervisor TPG, which has actually supported biotechs like Sionna Therapeutics as well as San...

Merck stops phase 3 TIGIT trial in bronchi cancer for futility

.Merck &amp Co.'s TIGIT system has actually gone through one more trouble. Months after shuttering a...

After a tough year, Exscientia folds in to Recursion

.After a year defined through pipe cuts, the departure of its own chief executive officer as well as...

Cullinan, after $25M offer, hands back bispecific to Harbour

.Cullinan Rehab was actually excited enough with Harbour BioMed's bispecific immune system reactor t...

A better look at Intense Biotech's Brutal 15

.In this particular week's incident of "The Best Pipe," our team are actually diving right into Stro...

Lilly encounters stage 2 failure of tau-targeting med

.The confetti is still soaring from Eli Lilly's gathering celebrating the commendation of Alzheimer'...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Invite to this week's Chutes &amp Ladders, our roundup of considerable management hirings, firings ...

Lykos will definitely talk to FDA to reevaluate its own decision following rejection of MDMA therapy for trauma

.Adhering to a poor presenting for Lykos Therapeutics' MDMA prospect for trauma at a current FDA con...

AN 2 one-halfs head count, quits period 3 test after information disappoint

.AN2 Therapeutics is reviewing its business in feedback to dull midphase information, swearing to la...

Merck spends $700M for bispecific, spying autoimmune position as well as chance to challenge Amgen in cancer cells

.Merck &amp Co. is paying for $700 thousand upfront to challenge Amgen in a blood stream cancer mark...